Table 4. Patient, disease, and treatment... | American Society of Hematology

Table 4.

Patient, disease, and treatment characteristics associated with risk of failure (new treatment, relapse, or death)

Characteristic at start of second-line treatment	Univariate analysis			Multivariable analysis
Characteristic at start of second-line treatment	HR	95% CI	P	HR	95% CI	P
Age at second-line treatment (per decade)	1.16	1.07-1.25	.0002
Weeks from transplant to first treatment (per week)	1.05	0.99-1.12	.10
Bilirubin (per mg/dL increase)	1.15	1.07-1.24	.0002	1.18	1.08-1.28	.0002
Albumin (per g/dL decrease)	2.27	1.82-2.84	$<$ ⁠.0001	1.87	1.42-2.46	$<$ ⁠.0001
Diarrhea	2.13	1.50-3.01	$<$ ⁠.0001
Any abdominal pain	2.10	1.53-2.89	$<$ ⁠.0001	1.39	0.94-2.06	.10
Stage 4 gut	2.61	1.81-3.78	$<$ ⁠.0001
No abdominal pain, no stage 4 gut	Ref†	NA	NA	Ref†	NA	NA
Any abdominal pain, no stage 4 gut*	1.65	1.12-2.41	.01	1.17	0.71-1.91	.54
Any Abdominal pain with stage 4 gut	3.06	2.05-4.56	<.0001	2.96	1.76-4.98	<.0001
Overt GI hemorrhage	3.53	1.78-7.01	.0003
HCT-CI (per unit)	1.12	1.04-1.22	.004
Steroid dose (per mg/kg prednisone equivalent)	1.73	1.25-2.39	$<$ ⁠.0001
Skin stage (per stage)	0.78	0.69-0.88	$<$ ⁠.0001
Body surface with rash (per 10%)	0.90	0.86-0.95	$<$ ⁠.0001
Number of prior transplants	1.19	0.84-1.70	.33
Transplant year (per year)	1.03	0.99-1.08	.15
Weeks from first treatment to second treatment (per week)	0.96	0.92-1.00	.05
Fever	0.82	0.39-1.76	.62
Active infection	0.88	0.58-1.32	.54
Agent						Global P = .69
Extracorporeal photopheresis	Ref†	NA	NA	Ref†	NA	NA
α-1 antitrypsin	3.08	1.37-6.94	.007	1.58	0.68-3.67	.29
ATG	2.07	1.00-4.28	.05	1.12	0.52-2.40	.77
Infliximab	1.69	0.71-4.01	.24	1.04	0.43-2.52	.94
Mycophenolate mofetil (not used for prophylaxis)	0.88	0.41-1.88	.73	1.03	0.47-2.27	.94
Sirolimus	0.96	0.45-2.08	.92	0.98	0.45-2.11	.96
Other	1.59	0.75-3.37	.23	1.42	0.67-3.04	.36

Characteristic at start of second-line treatment	Univariate analysis			Multivariable analysis
Characteristic at start of second-line treatment	HR	95% CI	P	HR	95% CI	P
Age at second-line treatment (per decade)	1.16	1.07-1.25	.0002
Weeks from transplant to first treatment (per week)	1.05	0.99-1.12	.10
Bilirubin (per mg/dL increase)	1.15	1.07-1.24	.0002	1.18	1.08-1.28	.0002
Albumin (per g/dL decrease)	2.27	1.82-2.84	$<$ ⁠.0001	1.87	1.42-2.46	$<$ ⁠.0001
Diarrhea	2.13	1.50-3.01	$<$ ⁠.0001
Any abdominal pain	2.10	1.53-2.89	$<$ ⁠.0001	1.39	0.94-2.06	.10
Stage 4 gut	2.61	1.81-3.78	$<$ ⁠.0001
No abdominal pain, no stage 4 gut	Ref†	NA	NA	Ref†	NA	NA
Any abdominal pain, no stage 4 gut*	1.65	1.12-2.41	.01	1.17	0.71-1.91	.54
Any Abdominal pain with stage 4 gut	3.06	2.05-4.56	<.0001	2.96	1.76-4.98	<.0001
Overt GI hemorrhage	3.53	1.78-7.01	.0003
HCT-CI (per unit)	1.12	1.04-1.22	.004
Steroid dose (per mg/kg prednisone equivalent)	1.73	1.25-2.39	$<$ ⁠.0001
Skin stage (per stage)	0.78	0.69-0.88	$<$ ⁠.0001
Body surface with rash (per 10%)	0.90	0.86-0.95	$<$ ⁠.0001
Number of prior transplants	1.19	0.84-1.70	.33
Transplant year (per year)	1.03	0.99-1.08	.15
Weeks from first treatment to second treatment (per week)	0.96	0.92-1.00	.05
Fever	0.82	0.39-1.76	.62
Active infection	0.88	0.58-1.32	.54
Agent						Global P = .69
Extracorporeal photopheresis	Ref†	NA	NA	Ref†	NA	NA
α-1 antitrypsin	3.08	1.37-6.94	.007	1.58	0.68-3.67	.29
ATG	2.07	1.00-4.28	.05	1.12	0.52-2.40	.77
Infliximab	1.69	0.71-4.01	.24	1.04	0.43-2.52	.94
Mycophenolate mofetil (not used for prophylaxis)	0.88	0.41-1.88	.73	1.03	0.47-2.27	.94
Sirolimus	0.96	0.45-2.08	.92	0.98	0.45-2.11	.96
Other	1.59	0.75-3.37	.23	1.42	0.67-3.04	.36

HR, hazard ratio; NA, not applicable.

This group also included the 2 patients with no abdominal pain and stage 4 gut involvement because of overt hemorrhage.

†

Reference groups were used as the comparison for other groups.

View Large

This Feature Is Available To Subscribers Only